Literature DB >> 31938235

High expression of SALL4 is associated with poor prognosis in squamous cell carcinoma of the uterine cervix.

Chunchan Di1, Jing Sun2, Hongwei Zhang3, Ping Zhou1, Jienan Kong4.   

Abstract

Background: The zinc-finger transcription factor Sal-like protein 4 (SALL4) plays a pivotal role in tumor invasion and metastasis. Here, we investigated the clinicopathological significance of SALL4 overexpression in cervical squamous cell carcinoma (SCC) of the uterine cervix.
Methods: SALL4 immunohistochemical staining was performed on cervical SCC specimens from 129 patients, as well as 98 cases of cervical squamous intraepithelial lesion (LSIL and HSIL) and 29 normal cervix samples. SALL4 immunofluorescence staining was performed in CaSki and SiHa cervical cancer cells. Statistical analyses were applied to evaluate correlations between SALL4 overexpression and clinicopathological features of SCC patients. Survival rates were calculated using the Kaplan-Meier method, and relationships between prognostic factors and patient survival were analyzed using Cox proportional hazard models.
Results: SALL4 protein showed mainly nuclear staining in cervical cancer cells. Strong diffuse SALL4 staining was frequently seen in cervical cancer compared with normal tissues. SALL4 expression was significantly higher in cervical cancers than in LSIL, HSIL, and normal cervical epithelia. SALL4 overexpression was positively correlated with poor differentiation, late-stage, and lymph node metastasis. Moreover, the 5-year survival rate of early-stage cervical cancer patients with high SALL4 expression was significantly lower than patients with low SALL4 expression. Multivariate analysis suggested that SALL4 protein expression is an independent risk factor for survival in SCC. Conclusions: SALL4 plays an important role in SCC progression. High-level SALL4 expression is an independent prognostic factor of poor outcomes in SCC. IJCEP
Copyright © 2018.

Entities:  

Keywords:  SALL4; cervical cancer; immunohistochemistry; prognosis

Year:  2018        PMID: 31938235      PMCID: PMC6958135     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  3 in total

1.  Knockdown of SALL4 inhibits the proliferation, migration, and invasion of human lung cancer cells in vivo and in vitro.

Authors:  Jiaping Li; Yan Zhang; Xinlu Tao; Qi You; Zheng Tao; Yan Zhang; Zhijie He; Jun Ou
Journal:  Ann Transl Med       Date:  2020-12

Review 2.  SALL4 Oncogenic Function in Cancers: Mechanisms and Therapeutic Relevance.

Authors:  Boshu Sun; Liangliang Xu; Wenhui Bi; Wen-Bin Ou
Journal:  Int J Mol Sci       Date:  2022-02-12       Impact factor: 5.923

Review 3.  SALL4: An Intriguing Therapeutic Target in Cancer Treatment.

Authors:  Shiva Moein; Daniel G Tenen; Giovanni Amabile; Li Chai
Journal:  Cells       Date:  2022-08-20       Impact factor: 7.666

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.